Projected worldwide oncology drugs revenue by 2030, up from US$232.50bn in 2026.
Reverse translational immuno-oncology for partnering-ready assets.
MIORG is a Finnish preclinical immuno-oncology biotech advancing therapeutic and diagnostic assets from patient-derived tumor biology. The company uses reverse translational precision oncology to discover immune-resistance mechanisms, validate targets, and translate them into therapeutic peptides, monoclonal antibodies, and biomarker-guided diagnostic tools.
- Preclinical proof-of-concept focus
- Therapeutic and diagnostic assets
- Built for pharma partnering
- Founder-led translational science
Reverse translational immuno-oncology company based in Finland.
4 therapeutic programs and 2 diagnostic programs positioned for preclinical advancement.
Business model centered on asset generation, licensing, and pharmaceutical partnering.
A growing need for therapies that expand the benefit of cancer immunotherapy.
Oncology remains one of the largest and fastest-moving pharmaceutical markets. Growth is increasingly shaped by immunotherapy, biologics, biomarker-guided treatment decisions, and technology-enabled drug discovery. For MIORG, the commercial logic is clear: better resistance biology can support better rational combinations, stronger patient-selection strategies, and more partnerable preclinical assets.
Projected global cancer immunotherapy market size by 2031, compared with US$83.6bn in 2023.
Projected global AI drug discovery market size by 2032, supporting demand for faster asset generation.
Markets aligned with MIORG’s strategy
Resistance and combination biology remain central
Preclinical asset generation for pharma partnering
Commercial value is moving toward mechanism-based, biomarker-informed development.
Resistant, cold, and immune-excluded tumors create a major gap for current immunotherapy. MIORG is designed to create value before clinical execution: discover clinically grounded immune-resistance mechanisms, validate them functionally, design therapeutic antibodies and peptides, and package biomarker-supported preclinical assets for licensing, co-development, or pharmaceutical partnering.
A preclinical platform designed to convert human tumor biology into partnering-ready assets.
MIORG is designed to identify immune-resistance mechanisms that matter in patients, validate their functional role in tumor immunogenicity and antitumor immunity, and advance programs toward preclinical proof-of-concept with a clear path to pharmaceutical partnering.
Patient-derived starting point
Reverse translation begins with clinically relevant biospecimens, resistance phenotypes, and tumor-immune biology observed in human disease contexts.
Therapeutic and diagnostic outputs
Programs are translated into therapeutic peptides, monoclonal antibodies, and diagnostic tools that support patient selection and program positioning.
Partnering-led development model
MIORG advances assets through validation and proof-of-concept with the goal of licensing, partnering, or progression into IND-enabling development with pharmaceutical collaborators.
Cancer immunotherapy still leaves major resistance biology unresolved.
Immune checkpoint therapy transformed oncology, but durable benefit remains limited by poor tumor immunogenicity, impaired antigen presentation, innate-adaptive immune crosstalk failure, and cold or immune-desert tumor states. MIORG is focused on discovering actionable resistance mechanisms that can be translated into tractable immunotherapy programs.
Large patient populations still derive limited benefit from current immunotherapy approaches.
Patient-derived biology can reveal resistance pathways that are obscured in generic discovery models.
Mechanism-based therapeutic and diagnostic assets support clearer positioning for future pharma development.
Patient-derived discovery to therapeutic design.
MIORG integrates reverse translational precision oncology, systems immunology, and functional validation to move from resistance biology to therapeutic and diagnostic asset generation.
1. Patient-derived discovery
Clinically annotated biospecimens and tumor phenotypes reveal immune-resistance mechanisms emerging in patients.
2. Target validation
Mechanisms are tested for their role in antigen presentation, tumor immunogenicity, and antitumor T-cell activity.
3. Therapeutic design
Validated biology is translated into therapeutic peptide programs, monoclonal antibody programs, and rational combinations.
4. Functional and in vivo PoC
Programs advance through preclinical functional and in vivo proof-of-concept to clarify biological and partnering value.
5. Partnering pathway
Selected assets are positioned for licensing, partnering, or progression toward IND-enabling development with pharma partners.
Biomarker-informed layer
Targeted transcriptomic assay + algorithm programs support patient selection, treatment stratification, and asset positioning.
A focused portfolio spanning therapeutic and diagnostic assets.
MIORG’s pipeline combines monoclonal antibody programs, therapeutic peptide programs, and companion diagnostic / clinical decision-support tools aligned with immune-resistance biology.
Invaritin (MIO-7436)
Therapeutic peptide program in metastatic cutaneous melanoma advancing through in vivo proof-of-concept.
MIO-36
Monoclonal antibody program for melanoma and solid tumors in lead optimization.
Nexorin (MIO-7071)
Discovery-stage therapeutic peptide program focused on immune-receptor-associated resistance biology.
Nexlimomab (MIO-7072)
Monoclonal antibody program for melanoma and solid tumors advancing through lead optimization.
MIORG MelanPD1 Dx (MIO-2101)
Targeted transcriptomic assay + algorithm designed to support response stratification in metastatic cutaneous melanoma.
MIORG UvealMet Dx (MIO-5201)
Targeted transcriptomic prognostic program for uveal melanoma based on immune-metabolic tumor signatures.
Mechanism-based assets designed for rational immunotherapy development.
MIORG’s therapeutic programs are built around antigen-presentation-associated immune resistance and immune-receptor-associated resistance mechanisms identified through reverse translational analysis.
Antigen-presentation-associated resistance programs
Programs are designed to restore or reinforce tumor immunogenicity and antitumor immune activity where antigen-presentation biology is impaired.
Immune-receptor-associated resistance programs
Programs are designed to modulate immune-receptor-associated pathways that suppress effective innate-adaptive immune crosstalk in tumors.
Peptide modality
Therapeutic peptide programs offer a modular route to mechanism-focused intervention, optimization, and preclinical proof-of-concept generation.
Antibody modality
Monoclonal antibody programs are advanced through target validation and lead optimization to support future partnering and broader pharmaceutical development.
Biomarker tools that strengthen patient selection and program positioning.
Diagnostics are not positioned as MIORG’s sole identity; they are developed as a supporting layer that can improve stratification, prognostic insight, and therapeutic development decisions.
MIORG MelanPD1 Dx (MIO-2101)
Companion diagnostic / clinical decision-support tool using a targeted transcriptomic assay + algorithm to support immune checkpoint therapy response estimation.
MIORG UvealMet Dx (MIO-5201)
Prognostic test using a targeted transcriptomic immune-metabolic assay + algorithm to stratify high-risk uveal melanoma biology.
Preclinical asset generation for licensing and pharma partnering.
MIORG discovers immune-resistance targets from patient-derived tumor biology, validates their functional role in tumor immunogenicity and antitumor T-cell responses, and develops therapeutic antibodies, peptides, and diagnostic tools through preclinical proof-of-concept for partnering, licensing, or progression into broader pharmaceutical development pathways.
- Target discovery and validation
- Therapeutic asset design
- Preclinical proof-of-concept packages
- Licensing and partnering pathways
Translational leadership rooted in cancer immunology.
MIORG is led by Carlos Rogério Figueiredo, PhD, a cancer immunologist, translational scientist, and Adjunct Professor at the University of Turku. The company is built around founder-led scientific direction and a network of clinical, translational, business, and board advisors supporting program advancement.
The scientific strategy is designed to keep discovery anchored to clinically relevant biology while maintaining a practical path toward preclinical asset packages that are understandable to pharmaceutical partners.
Discuss MIORG’s investor and partnering strategy.
MIORG welcomes discussions with investors, strategic partners, and pharmaceutical collaborators interested in preclinical immunotherapy assets, reverse translational oncology, and partnership-led development models.